Greek And Lung
Results: Seventy-nine individuals were included (mean age 69.77 0.72 years); 24 stable IPF, 18 IPF-AE, 10 combined pulmonary fibrosis and emphysema, 7 Rheumatoid arthritis-UIP-ILDs and 20 controls. TL in all patients was significantly shorter compared to controls [mean T/S ratio (SE) 0.77 (0.05) vs 2.26 (0.36), p
greek and lung
Background: Workers in cotton industry are occupationally exposed to various dust-related hazards. The nature of these agents and the respective exposure levels depend on the cotton industry specific sector. These exposures could be associated with respiratory symptoms and changes in lung function parameters.
Conclusions: Swimmers have superior FEV1.0 independent of stature and age in comparison with both land based athletes and sedentary controls. In addition, male national standard swimmers have superior FEV1.0 independent of stature and age in comparison with male non-national standard swimmers. When years of training is controlled for, the difference in FEV1.0 between the two groups is no longer evident. This suggests that the years of swimming training and/or the earlier age at which training begins may have a significant influence on subsequent FEV1.0 and swimming performance. However, because of the cross sectional nature of this study, the results do not exclude genetic endowment as a major determinant of the superior lung volume observed in swimmers.
Aim: The aim of the present case-control study was to examine the possible associations between periodontal disease indices and the risk of lung cancer development in a sample of Greek out-patients referred to a medical and a dental private practice.
Materials and methods: A total of 200 individuals were interviewed and underwent an oral clinical examination, and 64 of them were suffered from several histological types of lung cancer. The estimation of the possible associations between lung cancer as a dependent variable and periodontal disease indices as independent ones was carried out by using a multiple regression analysis model.
Results: Probing pocket depth (odds ratio (OR) = 2.72, 95% confidence interval (CI) 1.05-7.06), clinical attachment loss (OR = 3.51, 95% CI 1.30-9.47) bleeding on probing (OR = 1.93, 95% CI 0.98-3.81) were significantly associated with the risk of developing lung cancer. Smoking (OR = 2.49, 95% CI 1.20-5.17) was significantly associated with the mentioned risk, whereas it was consisted as a confounder regarding the estimated associations between moderate/severe clinical attachment loss and presence of bleeding on probing with the risk of developing lung cancer.
Dr. Galiatsatos is a pulmonary and critical care medicine physician. He is an expert in the diagnosis and treatment of obstructive lung disease, tobacco cessation, and in the care of critically ill patients in the Medical ICU. He is a member of the Obstructive Lung Disease Group at Johns Hopkins, oversees the Tobacco Treatment Clinic and provides teaching to medical students and residents at Johns Hopkins.
Objective: Greece has been affected more than any other European country from the financial crisis that began in 2010. Just 20 months after Greece exited an eight-year long aid program, forecasts of a new recession within 2020 due to COVID-19 pandemic make concerns regarding the compromise of health care quality within the new crisis relevant once again. In this study we sought to evaluate clinical outcomes in patients with advanced lung cancer in the pre-crisis and crisis era in a dedicated oncology centre in Greece. Methods: A retrospective analysis of 522 consecutive medical records of lung cancer patients admitted in a Greek dedicated cancer hospital between the years 2008-2013 was performed. Progression Free Survival (PFS) and Overall Survival (OS) were calculated for advanced lung cancer compared over two consecutive time periods using 2010 as a cutoff point.Result: 71 and 78 patients comprised the study sample for the two periods. PFS and OS were similar over the two periods (7.73 [6.42-9.04] vs. 6.03 [5.02-7.04] and 13.70 [9.61-17.79] vs. 11.08 [7.74-15.92] months, respectively). Higher Performance Status (PS) was associated with worse survival measures over both periods, while no statistical significance was reached for OS in the latter period. Dissimilarities in PFS were observed between beneficiaries of different insurance trusts. Conclusion: Clinical outcomes for advanced lung cancer have not changed as a result of the financial crisis in our institution. The insurance provider seems to affect health outcomes. This old paradigm could serve as new guidance in the forthcoming recession due to COVID-19 pandemic.
The exclusion criteria comprised of inconclusive diagnosis or initial staging, unexpected (for any reason) or early discontinuation of chemotherapy resulting in unacceptable delays and incomplete regimens, missing or impossible to interpret medical record data and concurrent malignancy of such biological behavior and extend, able to affect prognosis of lung cancer or stage I-III disease.
Tobacco smoking continues to be a major cause of COPD, while passive smoking may also contribute to respiratory symptoms and COPD progression [4, 6, 7]. Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, while on the contrary, smoking cessation has been found to reduce the rapid decline in FEV1 . Smoking cessation is the single most effective--and cost effective--way to reduce the possibility of developing COPD as smoking cessation can prevent or delay the development of airflow limitation, or reduce its progression . With the above in mind, active intervention to help patients quit smoking is a primary tool within the ideal management of COPD. Moreover, the Initiative for Chronic Obstructive Lung Disease includes goals related to clinical (prevention of disease progression and minimization of symptoms) and health-related quality of life (improved exercise tolerance and emotional function) among COPD patients indicating the interaction between respiratory illness and quality of life . Health status, functional status, and quality of life are three concepts often used interchangeably to refer to this same domain of health. Indeed, Health-Related Quality of Life (HRQL) is important for measuring the impact of chronic disease such as COPD. With the above initiative in mind, the necessity to develop new questionnaires that assess quality of life within COPD patients was emphasized so as to help determine and treat functional problems which are important in patients with COPD [11, 12]. However as the tool must be easy to use in clinical practice as also evaluate symptoms and the functional and intellectual situation of patients, the Clinical COPD Questionnaire (CCQ) was developed . With the above in mind the aim of the present study was to i) assess the CCQ's validity among both healthy adults and patients with COPD, ii) to assess the test-retest reliability of the CCQ and iii) to assess quality of life among COPD patients before and after smoking cessation.
Chronic obstructive pulmonary disease is a major cause of morbidity and mortality worldwide [1, 2]. Among patients with COPD the goals of clinical control include: improved exercise tolerance, emotional function, prevention of disease progression and minimization of symptoms, all of which may lead to an increased quality of life . Quality of life is an important factor in patient treatment and its scientific documentation is a necessity in clinical practice, for instance HRQL in patients with COPD is related to impaired FEV1 . With this in mind, the CCQ as seen through the context of this study, can pick up the differences noted between each state of COPD and thus help categorize each patient and assess their symptomatic, mental and functional status, with the latter found to be related to the clinical outcome of lung function tests. In general patients with mild COPD have better respiratory function test (FEV1, FEV1/FVC) than patients with moderate COPD, and this association was also indicated through our study [20, 21].
In 2014, the outlook for CF patients in Greece was poor. The best course of action for many patients is a lung transplant, but these were not offered in Greece at this time. Dimitris travelled to a transplant centre in Vienna, Austria, with the idea of building official contact with the centre to support Greek patients. After a year of negotiations and lobbying, Dimitris managed to establish an agreement that saw about 5 Greek patients a year receive a transplant at the AKH Transplant Centre in Vienna.
In November 2019, Dimitris took the unprecedented and selfless step of declining the offer of a lung transplant at the centre, after two years on the waiting list. He wanted to use this decision as an opportunity to urge the government to make a new cystic fibrosis transmembrane conductance regulator (CFTR) therapy available in Greece after it was approved for use in the USA the previous month (October 2019).
Lung cancer (40.2 new cases and 36.5 deaths/100.000 per year) is the most common type of cancer, followed by colorectal cancer (25.1 new cases and 14.7 deaths/100.000 per year) and breast cancer (56.8 new cases and 22.7 deaths/100.000 per year in women). There was a statistically significant increase of lung cancer in women in the last 22 years (a trend comparable with the one in EU countries, due to the increasing number of women who smoke), and of colorectal cancer, thyroid cancer, melanoma and non-Hodgkin malignant neoplasm in both sexes. There is also an increase in cervical cancer in women and leukemia in men. 041b061a72